Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK-506 in Pulmonary Arterial Hypertension
NCT01647945Phase 2Completed
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tacrolimus in pulmonary arterial hypertension (PAH) (4 arms). Primary endpoint: Safety of Low-dose FK-506 in PAH at 18 weeks. Started Jul 2012; status: completed.
02
Drugs
tacrolimus
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01647945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647945.